Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: A new anti-factor VIII inhibitory mechanism

Thrombosis and Haemostasis

Volumn 87, Issue 3, 2002, Pages 459-465

  Nogami, Keiji ^a   Shima, Midori ^a   Nishiya, Katsumi ^a   Sakurai, Yoshihiko ^a   Tanaka, Ichiro ^a   Giddings, John C ^a   Saenko, Evgueni L ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

C2 domain; Factor VIII; Factor Xa; Hemophilia A; Inhibitor

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; GLUTAMINE; GLYCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C2; PHOSPHOLIPID; THREONINE; UNCLASSIFIED DRUG; VALINE; BLOOD CLOTTING FACTOR 8; EPITOPE;

ANTIBODY DETECTION; ARTICLE; ASSAY; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING PARAMETERS; CASE REPORT; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BINDING; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; ANTIBODY SPECIFICITY; ENZYME ACTIVATION; HEMOPHILIA A; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

ANTIBODY SPECIFICITY; ENZYME ACTIVATION; EPITOPES; FACTOR VIII; FACTOR XA; HEMOPHILIA A; HUMANS; ISOANTIBODIES; PHOSPHOLIPIDS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 0036125866     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613026     Document Type: Article

References (33)

1. The role of phospholipid and factor VIIIa in the activation of bovine factor X
2. Expression of active human factor VIII from recombinant DNA clones
3. Structure of human factor VIII
4. Stabilization of factor VIII in plasma by the von Willebrand factor; Studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's disease
5. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein
6. The factor VIII complex: Structure and function
7. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity
8. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689
9. Role of factor VIII C2 domain in factor VIII binding to factor Xa
10. Von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain
11. The effect of von Willebrand factor on activation of factor VIII by factor Xa
12. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
13. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII
14. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site
15. Some human inhibitor antibodies interfere with factor VIII binding to factor IX
16. Inhibition of human factor VIIIa by anti-A2 subunit antibodies
17. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
18. A role for the C2 domain of factor VIII in binding to von Willebrand factor
19. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain
20. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition
21. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor
22. The phospholipid binding property of the C2 domain of human factor VIII
23. Binding to human factor VIII to phospholipid vesicles
24. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor
25. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: Requirement of Cys2326 and Glu2327 for maximum effect
26. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenyl-glycoluril
27. Preparation of anhydrothrombin and characterization of its interaction with normal thrombin substrates
28. 2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalyzed factor VIII activation
29. Structure of the C2 domain of human factor VIII at 1.5 Å resolution
30. Antigenicity of putative phospholipid membrane-binding residues in factor VIII
31. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII
32. Four hydrophobic amino acids in the factor VIII C2 domain are constituents of the membrane-binding and von Willebrand factor-binding motif
33. Structure of a factor VIII C2 domain-immunoglobulin G4k Fab complex: Identification of an inhibitory antibody epitope on the surface of factor VIII